Arcellx (ACLX) Expected to Announce Earnings on Thursday

Arcellx (NASDAQ:ACLX) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Arcellx Price Performance

ACLX stock opened at $69.04 on Thursday. The firm has a 50 day simple moving average of $67.26 and a two-hundred day simple moving average of $74.84. The stock has a market cap of $3.99 billion, a PE ratio of -17.57 and a beta of 0.36. Arcellx has a one year low of $47.86 and a one year high of $94.07.

Insider Activity

In related news, insider Christopher Heery sold 5,882 shares of the company’s stock in a transaction dated Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the transaction, the insider directly owned 23,749 shares in the company, valued at approximately $1,627,043.99. This represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 19,450 shares of company stock valued at $1,283,477. 8.35% of the stock is currently owned by company insiders.

Institutional Trading of Arcellx

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP grew its stake in shares of Arcellx by 25.0% during the third quarter. Quarry LP now owns 3,376 shares of the company’s stock worth $277,000 after acquiring an additional 675 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Arcellx in the 3rd quarter valued at $283,000. Integrated Wealth Concepts LLC raised its holdings in shares of Arcellx by 9.0% during the third quarter. Integrated Wealth Concepts LLC now owns 3,423 shares of the company’s stock valued at $281,000 after acquiring an additional 283 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Arcellx in the 3rd quarter valued at $430,000. Finally, Tower Research Capital LLC TRC raised its holdings in Arcellx by 105.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,143 shares of the company’s stock valued at $405,000 after acquiring an additional 3,147 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ACLX has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Arcellx in a research note on Thursday, February 5th. Canaccord Genuity Group reiterated a “buy” rating and set a $130.00 price target on shares of Arcellx in a research report on Monday, December 8th. Rothschild & Co Redburn downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 target price on the stock. in a report on Thursday, February 12th. Guggenheim restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.20.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.